Is the Sarepta mess what a political FDA looks like?news2025-07-29T13:31:27+00:00July 29th, 2025|Endpoints News|
Endpoints livestream: Is the Sarepta mess what a politicized FDA looks like?news2025-07-29T12:58:05+00:00July 29th, 2025|Endpoints News|
FDA investigates death of boy who got Elevidys, Roche says death unrelated to therapynews2025-07-26T09:32:16+00:00July 26th, 2025|Endpoints News|
CHMP recommends against Elevidys’ approval in Europenews2025-07-25T10:33:38+00:00July 25th, 2025|Endpoints News|
Rocket cuts 30% of staff as it plots path forward for gene therapiesnews2025-07-24T15:24:25+00:00July 24th, 2025|Endpoints News|
Sarepta would have to conduct new studies to get back on market, FDA official saysnews2025-07-24T15:17:46+00:00July 24th, 2025|Endpoints News|
Still in flux, Galapagos hires new execs, adjusts deal with Gilead, and considers selling its cell therapy businessnews2025-07-23T23:47:06+00:00July 23rd, 2025|Endpoints News|
Parker Institute, ARCH unveil CAR-T biotech with $216M to crack solid tumorsnews2025-07-23T10:30:41+00:00July 23rd, 2025|Endpoints News|
Circular RNA startup Orbital unveils first monkey data as it enters in vivo CAR-T cell therapy racenews2025-07-22T10:00:54+00:00July 22nd, 2025|Endpoints News|
Endpoints livestream: What happens next with Sarepta’s Duchenne crisis? news2025-07-21T15:14:09+00:00July 21st, 2025|Endpoints News|
